Astrana Health/$ASTH
1D1W1MYTD1Y5YMAX
Capital at risk
About Astrana Health
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
- Ticker
- $ASTH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 3,000
- Headquarters
- Alhambra, United States
- Website
- www.astranahealth.com
Astrana Health Metrics
BasicAdvanced
$1.9B
46.32
$0.82
0.90
-
Price and volume
Market cap
$1.9B
Beta
0.9
52-week high
$51.60
52-week low
$18.08
Average daily volume
411K
Financial strength
Current ratio
1.229
Quick ratio
1.19
Long term debt to equity
153.134
Total debt to equity
163.623
Dividend payout ratio (TTM)
4.57%
Interest coverage (TTM)
1.66%
Profitability
EBITDA (TTM)
183.078
Gross margin (TTM)
10.46%
Net profit margin (TTM)
1.05%
Operating margin (TTM)
2.91%
Effective tax rate (TTM)
34.73%
Revenue per employee (TTM)
$1,280,000
Management effectiveness
Return on assets (TTM)
4.03%
Return on equity (TTM)
6.90%
Valuation
Price to earnings (TTM)
46.32
Price to revenue (TTM)
0.486
Price to book
2.25
Price to tangible book (TTM)
-6.23
Price to free cash flow (TTM)
19.78
Free cash flow yield (TTM)
5.06%
Free cash flow per share (TTM)
1.92
Growth
Revenue change (TTM)
58.91%
Earnings per share change (TTM)
56.78%
3-year revenue growth (CAGR)
43.66%
3-year earnings per share growth (CAGR)
-6.12%
What the Analysts think about Astrana Health
Analyst ratings (Buy, Hold, Sell) for Astrana Health stock.
Analyst projections of the future price of Astrana Health stock.
Bulls say / Bears say
Q2 2026 demonstrated strong execution: revenue rose 49% year over year, adjusted EBITDA increased 43%, and diluted adjusted EPS grew 45%; management also raised its 2026 adjusted EBITDA guidance. (Astrana Health)
Cash conversion improved materially, with $100.8 million of operating cash flow and $92.9 million of free cash flow in the first half of 2026, providing funding for reinvestment, acquisitions, and debt reduction. (Astrana Health)
The company has evidence of scalable value-based-care economics: affiliated ACOs generated $120.4 million of gross shared savings for the 2024 performance year, while new Hawaii and Texas Medicare Advantage agreements expanded its addressable footprint. (Astrana Health)
Astrana’s model is increasingly exposed to medical-cost volatility: 81% of Q2 2026 capitation revenue came from full-risk arrangements, meaning unfavorable utilization or acuity trends could pressure margins and earnings. (SEC)
Revenue remains highly concentrated in Care Partners, which generated $932.8 million of $972.5 million in Q2 2026 revenue; dependence on this segment, payer relationships, and Medicare Advantage economics increases concentration risk. (Astrana Health)
Astrana disclosed a material weakness in internal controls over financial reporting related to business-combination accounting, and it previously needed an extension to file its 2025 Form 10-K; further acquisition or integration complexity could undermine reporting reliability. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Astrana Health Financial Performance
Revenues and expenses
Astrana Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Astrana Health News
AllArticlesVideos
Funds containing Astrana Health
AllUSDEURGBP
Fund name | Fund size | $ASTH weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.17% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.17% |
iShares Healthcare Innovation£DRDR | £1B | 0.17% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.09% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.09% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.